Difference between revisions of "Apatinib (Aitan)"
Jump to navigation
Jump to search
m |
m |
||
| Line 25: | Line 25: | ||
[[Category:Hepatocellular carcinoma medications]] | [[Category:Hepatocellular carcinoma medications]] | ||
| − | [[Category: | + | [[Category:NMPA approved drugs]] |
Revision as of 12:08, 22 April 2022
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Diseases for which it is used
Also known as
- Code name: YN968D1
- Generic name: rivoceranib
- Brand name: Aitan